Covid-19 booster shots take centre stage
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
Europe approves a Covid-19 crystal ball
Memed claims that its newly CE-marked test can predict Covid-19 severity.
The Delta for Covid-19 vaccine efficacy
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Smaller medtechs suffer, but not from Covid-19
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Covid-19 booster shots take centre stage
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
Europe approves a Covid-19 crystal ball
Memed claims that its newly CE-marked test can predict Covid-19 severity.
The Delta for Covid-19 vaccine efficacy
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Smaller medtechs suffer, but not from Covid-19
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
